Healthcare provider profile · identity verified

Ihsan Hamoudi, MD.

Family Practice · ANAHEIM, CA · NPI 1972942266

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	204	111
Rosuvastatin Calcium	Rosuvastatin Calcium	204	98
Ozempic	Semaglutide	145	28
Pantoprazole Sodium	Pantoprazole Sodium	139	51
Amlodipine Besylate	Amlodipine Besylate	136	67
Losartan Potassium	Losartan Potassium	128	68
Levothyroxine Sodium	Levothyroxine Sodium	110	41
Lisinopril	Lisinopril	99	42
Atenolol	Atenolol	90	39
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	89	33
Tamsulosin Hcl	Tamsulosin Hcl	86	38
Azelastine Hcl	Azelastine Hcl	84	50
Gabapentin	Gabapentin	79	42
Finasteride	Finasteride	73	22
Metformin Hcl	Metformin Hcl	70	28
Metformin Hcl Er	Metformin Hcl	70	28
Jardiance	Empagliflozin	63	28
Furosemide	Furosemide	57	28
Alendronate Sodium	Alendronate Sodium	54	28
Ezetimibe	Ezetimibe	51	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	45	27
Spironolactone	Spironolactone	45	16
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	44	17
Metoprolol Tartrate	Metoprolol Tartrate	44	17
Meloxicam	Meloxicam	40	31
Allopurinol	Allopurinol	39	18
Pradaxa	Dabigatran Etexilate Mesylate	39	15
Trazodone Hcl	Trazodone Hcl	39	23
Glipizide	Glipizide	35	12
Terazosin Hcl	Terazosin Hcl	35	16
Tramadol Hcl	Tramadol Hcl	34	15
Bisoprolol Fumarate	Bisoprolol Fumarate	32	13
Omeprazole	Omeprazole	31	18
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	29	12
Donepezil Hcl	Donepezil Hcl	28	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	27	17
Ipratropium Bromide	Ipratropium Bromide	27	13
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	26	suppressed
Bupropion Xl	Bupropion Hcl	25	12
Humulin N Kwikpen	Insulin Nph Human Isophane	25	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	23	11
Simvastatin	Simvastatin	22	13
Famotidine	Famotidine	21	12
Humulin N	Insulin Nph Human Isophane	21	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	20	20
Glipizide Er	Glipizide	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Spiriva Respimat	Tiotropium Bromide	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	11
Sulindac	Sulindac	18	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	17	14
Triamcinolone Acetonide	Triamcinolone Acetonide	17	14
Chlorhexidine Gluconate	Chlorhexidine Gluconate	16	13
Citalopram Hbr	Citalopram Hydrobromide	16	suppressed
Lovastatin	Lovastatin	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Prednisone	Prednisone	16	16
Carvedilol	Carvedilol	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	15	15
Eliquis	Apixaban	15	suppressed
Humulin R	Insulin Regular, Human	15	suppressed
Montelukast Sodium	Montelukast Sodium	15	suppressed
Sertraline Hcl	Sertraline Hcl	15	suppressed
Alvesco	Ciclesonide	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Colchicine	Colchicine	13	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Mirtazapine	Mirtazapine	12	suppressed
Nitroglycerin	Nitroglycerin	12	11
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Trospium Chloride	Trospium Chloride	12	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Alprazolam	Alprazolam	11	11
Doxycycline Hyclate	Doxycycline Hyclate	11	suppressed
Estradiol	Estradiol	11	suppressed
Lactulose	Lactulose	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error